1476720-72-5

Upstream product

• 72-18-4 L-valine 
• 268224-29-9 (R)-3,3-dimethyl-[1,3]azasilolidine-1,5-dicarboxylic acid 1-tert-butyl ester 
• 1476720-71-4 (R)-5-[4-(4-bromo-phenyl)-1H-imidazol-2-yl]-3,3-dimethyl-[1,3]azasilolidine 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 1334313-74-4 (R)-3,3-dimethyl-[1,3]azasilolidine-1,5-dicarboxylic acid 5-[2-(4-bromo-phenyl)-2-oxo-ethyl]ester 1-tert-butyl ester 

Downstream Products

• 1476720-73-6 [(S)-1-((R)-3,3-dimethyl-5-{4-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-1H-imidazol-2-yl}-[1,3]azasilolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methylester 

Relevant academic research and scientific papers

HEPATITIS C VIRUS INHIBITORS

The invention provides compounds of formulas (I) or (II): wherein the variables are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are inhibitors of replication of the hepatitis C virus. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat hepatitis C viral infections, and processes and intermediates useful for preparing such compounds.